Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29617917 | 0.77 | ALDH1A1 (0.42) | ALDH1A1LMNAMAPTHSD17B10CA1 | |
| SCHEMBL5138286 | 0.76 | MEN1 (0.33) | ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL450880 | 0.75 | CHRM1 (0.38) | — | |
| SCHEMBL30891245 | 0.73 | RET (0.40) | POLBMEN1KMT2AHSD17B10KDM4E | |
| SCHEMBL11380880 | 0.73 | RET (0.40) | POLBMEN1KMT2AHSD17B10KDM4E | |
| SCHEMBL8302403 | 0.73 | HTR2B (0.36) | ALDH1A1 | |
| SCHEMBL16168528 | 0.72 | MEN1 (0.43) | ALDH1A1POLBMEN1KMT2ALMNA | |
| SCHEMBL29791776 | 0.71 | ALDH1A1 (0.59) | ALDH1A1POLBMEN1KMT2AHSD17B10 | |
| SCHEMBL6268156 | 0.70 | ALDH1A1 (0.35) | ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL868796 | 0.70 | ALDH1A1 (0.53) | ALDH1A1POLBMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4578500-A2 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS | Amazentis SA (CH) | 2025-07-02 | — | — | EP | disclosed |
| US-12310943-B2 | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders | AMAZENTIS SA (CH) | 2025-05-27 | — | — | US | disclosed |
| EP-3369420-B1 | NON-THERAPEUTIC USE OF UROLITHIN A FOR IMPROVING COGNITIVE FUNCTION. | AMAZENTIS SA (CH) | 2025-03-12 | — | — | EP | disclosed |
| EP-3372228-B1 | NON-THERAPEUTIC METHOD OF INCREASING OR MAINTAINING MITOCHONDRIAL FUNCTION | AMAZENTIS SA (CH) | 2025-03-12 | — | — | EP | disclosed |
| US-12036205-B2 | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders | AMAZENTIS SA (CH) | 2024-07-16 | — | — | US | disclosed |
| US-20240156777-A1 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS | AMAZENTIS SA (CH) | 2024-05-16 | — | — | US | disclosed |
| US-20240100016-A1 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS | AMAZENTIS SA (CH) | 2024-03-28 | — | — | US | disclosed |
| US-11903922-B2 | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders | AMAZENTIS SA (CH) | 2024-02-20 | — | — | US | disclosed |
| US-20220280475-A1 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS | AMAZENTIS SA (CH) | 2022-09-08 | — | — | US | disclosed |
| US-11234960-B2 | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders | AMAZENTIS SA (CH) | 2022-02-01 | — | — | US | disclosed |
| EP-3278800-A2 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING MUSCLE-RELATED PATHOLOGICAL CONDITIONS | Amazentis SA (CH) | 2018-02-07 | — | — | EP | disclosed |
| US-9872850-B2 | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders | AMAZENTIS SA (CH) | 2018-01-23 | — | — | US | disclosed |
| US-20170143667-A1 | Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders | AMAZENTIS SA (CH) | 2017-05-25 | — | — | US | disclosed |
| US-20170143666-A1 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS | AMAZENTIS SA (CH) | 2017-05-25 | — | — | US | disclosed |
| US-20160213641-A1 | Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2016-07-28 | — | — | US | disclosed |
| US-20160213643-A1 | Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders | AMAZENTIS SA (CH) | 2016-07-28 | — | — | US | disclosed |
| EP-2654461-A2 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODENEGENERATIVE DISEASES AND COGNITIVE DISORDERS | Amazentis SA (CH) | 2013-10-30 | — | — | EP | disclosed |
| US-20120164243-A1 | Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders | AMAZENTIS SA (CH) | 2012-06-28 | — | — | US | disclosed |
| WO-2012088519-A2 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODENEGENERATIVE DISEASES AND COGNITIVE DISORDERS | AMAZENTIS SA (CH) | 2012-06-28 | — | — | WO | disclosed |
| EP-0003883-B1 | AMINO-DIBENZOPYRANS, THEIR PREPARATION, FORMULATIONS CONTAINING THEM AND THEIR USE AS PHARMACEUTICALS | ELI LILLY AND COMPANY (US) | 1982-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12310943-B2 | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders | NLN, TUFM, TFAM | ALDH1A1 2051/4885POLB 1218/4885MEN1 1675/4885 |
| US-20120164243-A1 | Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders | NLN, TUFM, TFAM | ALDH1A1 2051/4885POLB 1218/4885MEN1 1675/4885 |
| US-20170143666-A1 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS | NLN, TUFM, TFAM | ALDH1A1 1949/4885POLB 1052/4885MEN1 2315/4885 |
| US-20160213643-A1 | Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders | NLN, TUFM, TFAM | ALDH1A1 2051/4885POLB 1218/4885MEN1 1675/4885 |
| US-11903922-B2 | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders | NLN, TUFM, TFAM | ALDH1A1 2051/4885POLB 1218/4885MEN1 1675/4885 |
| US-11234960-B2 | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders | NLN, TUFM, TFAM | ALDH1A1 2051/4885POLB 1218/4885MEN1 1675/4885 |
| US-20160213641-A1 | Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders | NLN, TUFM, TFAM | ALDH1A1 2051/4885POLB 1218/4885MEN1 1675/4885 |
| US-20240156777-A1 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS | NLN, TUFM, TFAM | ALDH1A1 2051/4885POLB 1218/4885MEN1 1675/4885 |
| US-20170143667-A1 | Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders | NLN, TUFM, TFAM | ALDH1A1 2051/4885POLB 1218/4885MEN1 1675/4885 |
| US-20240100016-A1 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS | NLN, TUFM, TFAM | ALDH1A1 2051/4885POLB 1218/4885MEN1 1675/4885 |
| US-12036205-B2 | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders | NLN, TUFM, TFAM | ALDH1A1 2051/4885POLB 1218/4885MEN1 1675/4885 |
| US-20220280475-A1 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS | NLN, TUFM, TFAM | ALDH1A1 2051/4885POLB 1218/4885MEN1 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.